MX2023005027A - Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. - Google Patents
Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados.Info
- Publication number
- MX2023005027A MX2023005027A MX2023005027A MX2023005027A MX2023005027A MX 2023005027 A MX2023005027 A MX 2023005027A MX 2023005027 A MX2023005027 A MX 2023005027A MX 2023005027 A MX2023005027 A MX 2023005027A MX 2023005027 A MX2023005027 A MX 2023005027A
- Authority
- MX
- Mexico
- Prior art keywords
- hair loss
- deuterated
- regimens
- treatment
- loss disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063106790P | 2020-10-28 | 2020-10-28 | |
| US202163155637P | 2021-03-02 | 2021-03-02 | |
| PCT/US2021/057123 WO2022094133A1 (en) | 2020-10-28 | 2021-10-28 | Regimens for the treatment of hair loss disorders with deuterated jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005027A true MX2023005027A (es) | 2023-07-31 |
Family
ID=78725692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005027A MX2023005027A (es) | 2020-10-28 | 2021-10-28 | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230390292A1 (https=) |
| EP (1) | EP4236956A1 (https=) |
| JP (1) | JP2023553253A (https=) |
| KR (1) | KR20230093504A (https=) |
| AU (1) | AU2021372512A1 (https=) |
| CA (1) | CA3196551A1 (https=) |
| CL (1) | CL2023001201A1 (https=) |
| CO (1) | CO2023006808A2 (https=) |
| DO (1) | DOP2023000085A (https=) |
| IL (1) | IL302401A (https=) |
| JO (1) | JOP20230090A1 (https=) |
| MX (1) | MX2023005027A (https=) |
| PE (1) | PE20231945A1 (https=) |
| WO (1) | WO2022094133A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3250876A1 (en) * | 2022-05-04 | 2023-11-09 | Sun Pharmaceutical Industries, Inc. | DOSAGE REGIMEN FOR TREATMENT WITH DEUTERATED JAK INHIBITORS |
| US12364699B2 (en) * | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
| US12247034B1 (en) * | 2024-04-19 | 2025-03-11 | Sun Pharmaceutical Industries, Inc. | Crystalline form of deuruxolitinib phosphate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| CN1255185C (zh) | 2001-05-03 | 2006-05-10 | 弗·哈夫曼-拉罗切有限公司 | 无定形甲磺酸奈非那韦的药物剂型 |
| MX2007003731A (es) | 2004-09-29 | 2007-08-14 | Johnson & Johnson | Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables. |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| TWI720517B (zh) | 2009-01-15 | 2021-03-01 | 美商英塞特公司 | 製造ｊａｋ抑制劑之方法及相關中間化合物 |
| HRP20250965T1 (hr) | 2012-06-15 | 2025-10-10 | Sun Pharmaceutical Industries, Inc. | Deuterirani derivati ruksolitiniba |
| ES2988629T3 (es) * | 2016-05-04 | 2024-11-21 | Sun Pharmaceutical Ind Inc | Tratamiento de trastornos de pérdida de cabello con inhibidores de JAK deuterados |
| AU2020219797B2 (en) | 2019-02-06 | 2025-10-16 | Sun Pharmaceutical Industries, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| CA3228505A1 (en) * | 2021-08-11 | 2023-02-16 | Sun Pharmaceutical Industries, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| US12364699B2 (en) * | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
-
2021
- 2021-10-28 AU AU2021372512A patent/AU2021372512A1/en active Pending
- 2021-10-28 US US18/033,730 patent/US20230390292A1/en active Pending
- 2021-10-28 CA CA3196551A patent/CA3196551A1/en active Pending
- 2021-10-28 IL IL302401A patent/IL302401A/en unknown
- 2021-10-28 PE PE2023001507A patent/PE20231945A1/es unknown
- 2021-10-28 EP EP21811647.3A patent/EP4236956A1/en active Pending
- 2021-10-28 WO PCT/US2021/057123 patent/WO2022094133A1/en not_active Ceased
- 2021-10-28 MX MX2023005027A patent/MX2023005027A/es unknown
- 2021-10-28 KR KR1020237017998A patent/KR20230093504A/ko active Pending
- 2021-10-28 JP JP2023526173A patent/JP2023553253A/ja active Pending
-
2023
- 2023-04-26 CL CL2023001201A patent/CL2023001201A1/es unknown
- 2023-04-27 JO JOJO/P/2023/0090A patent/JOP20230090A1/ar unknown
- 2023-04-28 DO DO2023000085A patent/DOP2023000085A/es unknown
- 2023-05-25 CO CONC2023/0006808A patent/CO2023006808A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023001201A1 (es) | 2023-11-17 |
| US20230390292A1 (en) | 2023-12-07 |
| JOP20230090A1 (ar) | 2023-04-27 |
| CA3196551A1 (en) | 2022-05-05 |
| IL302401A (en) | 2023-06-01 |
| PE20231945A1 (es) | 2023-12-05 |
| AU2021372512A1 (en) | 2023-06-22 |
| KR20230093504A (ko) | 2023-06-27 |
| JP2023553253A (ja) | 2023-12-21 |
| EP4236956A1 (en) | 2023-09-06 |
| CO2023006808A2 (es) | 2023-09-08 |
| WO2022094133A9 (en) | 2023-05-19 |
| WO2022094133A1 (en) | 2022-05-05 |
| DOP2023000085A (es) | 2023-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005027A (es) | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. | |
| EP4424367A3 (en) | Treatment of hair loss disorders with deuterated jak inhibitors | |
| MX2024000820A (es) | Compuestos para la inhibicion de proteinas que contienen el dominio de pirina de la familia nlr 3 (nlrp3) y usos de estos. | |
| MX2024000271A (es) | Inhibidor de shp2 y uso del mismo. | |
| MX2021011928A (es) | Composiciones y metodos para el tratamiento de enfermedades o trastornos asociados con kras. | |
| MX2025003908A (es) | Compuesto inhibidor de parg | |
| ZA202206485B (en) | Use of bi853520 in cancer treatment | |
| MX2023010728A (es) | Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor. | |
| PH12022553501A1 (en) | Alk2 inhibitors for the treatment of anemia | |
| MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. | |
| MX2024014317A (es) | Tratamientos con nirogacestat | |
| MX2024014121A (es) | Metodos y composiciones para el tratamiento del exceso de glucocorticoides | |
| MX2024006678A (es) | Inhibidor de cdk4 para el tratamiento del cancer. | |
| MX2022015146A (es) | Tratamiento de la artritis reumatoide. | |
| EA200500894A1 (ru) | Применение комбинации, содержащей ненуклеозидный ингибитор обратной транскриптазы (нниот) в сочетании с ингибитором цитохрома p450, таким как протеазные ингибиторы | |
| PH12021551975A1 (en) | Use of vibegron to treat overactive bladder | |
| MX2024013641A (es) | Regimenes de dosificacion para el tratamiento con inhibidores deuterados de jak | |
| PH12021553098A1 (en) | Treatment for synucleinopathies | |
| MX2025001316A (es) | Tratamiento de la urticaria con inhibidores de la cinasa de janus (jak) | |
| MX2023002422A (es) | Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson. | |
| WO2024026458A3 (en) | Use of glycogen metabolism inhibitors for the treatment of cancer | |
| JOP20240263A1 (ar) | مثبطات ripk1 وطرق الاستخدام | |
| EA201892360A1 (ru) | Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak | |
| MX2025010790A (es) | Inhibidores de la vía cinasa janus 1 (jak1) para el tratamiento del asma | |
| WO2024226493A3 (en) | Treatment of memory loss with phosphodiesterase inhibitors |